Molecular Genetics & Genomic Medicine (Jun 2019)

Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high‐risk breast cancer

  • Xiaozhen Wang,
  • Haimeng Liu,
  • Amina Maimaitiaili,
  • Gang Zhao,
  • Sijie Li,
  • Zheng Lv,
  • Di Wu,
  • Aiping Shi,
  • Xin Guan,
  • Hongyao Jia,
  • Menghan Li,
  • Dong Song,
  • Lihua Kang,
  • Bing Han,
  • Tong Fu,
  • Ming Yang,
  • Zhu Zhu,
  • Ye Du,
  • Yanqiu Song,
  • Jinghui Hong,
  • Zhimin Fan

DOI
https://doi.org/10.1002/mgg3.677
Journal volume & issue
Vol. 7, no. 6
pp. n/a – n/a

Abstract

Read online

Abstract Background Breast cancer is the most common cancer among women worldwide. Here, we report the prevalence of BRCA1/2 mutations in patients with high‐risk breast cancer from Inner Mongolia and Jilin, China, which was a part of a nationwide project on the detection of BRCA1/2 mutations in Chinese patients with hereditary breast cancer. Methods According to the criteria, index patients from a total of 245 independent families were initially recruited. All 49 exons of BRCA1 and BRCA2 and adjacent noncoding regions were screened for mutations based on next‐generation sequencing from collected saliva. Results We detected 17 BRCA1/2 variants in 18 of 216 (8.3%) index patients with high‐risk breast cancer. Among these, seven mutations were novel, including four BRCA1 mutations (c.123_124delCAinsAT, c.5093_5096delCTAA, c.5396‐2A>G, and c.2054delinsGAAGAGTAACAAGTAAGAAGAGTAACAAGAAG), and three BRCA2 mutations (c.304A>T, c.7552_7553insT, and c.9548_9549insA). The BRCA1/2 variants were identified in 14% (8/57) of the patients with triple‐negative breast cancer and in 6.3% (10/159) of the patients with non‐triple‐negative breast cancer. There was no significant difference between the two groups (p = 0.07). A higher frequency for BRCA1 mutations was observed in patients with triple‐negative breast cancer than in those with non‐triple‐negative breast cancer (12.3% vs. 2.5%, p = 0.004). The frequencies of the BRCA2 mutations were not significantly different between patients with triple‐negative breast cancer and those with non‐triple‐negative breast cancer (1.8% vs. 3.8%, p = 0.46). Conclusion We found that patients with triple‐negative breast cancer had a higher frequency of BRCA1 mutations than those with non‐triple‐negative breast cancer. In this study, no significant associations between the BRCA1/2 mutation status and age, family history of breast cancer, ovarian cancer, pancreatic cancer and prostate cancer, number of primary lesions, tumor size, or lymph node metastasis were observed.

Keywords